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Abstract
This study aimed to determine the clinical course of patients and the quality of antibiotic use using a systematic and unsolicited post-
prescription antibiotic review. Seven hundred and ﬁfty-three adult patients receiving antibiotic therapy for 3–5 days were randomized to
receive either a post-prescription review by the infectious disease physician (IDP), followed by a recommendation to the attending physician
to modify the prescription when appropriate, or no systematic review of the prescription. In the intervention group, 63.3% of prescriptions
prompted IDP recommendations, which were mostly followed by ward physicians (90.3%). Early antibiotic modiﬁcations were more
frequent in the intervention group (57.1% vs. 25.7%, p <0.0001), including stopping therapy, shortening duration and de-escalating broad-
spectrum antibiotics. IDP intervention led to a signiﬁcant reduction of the median [IQR] duration of antibiotic therapy (6 [4–9] vs. 7 days
[5–9], p <0.0001). In-hospital mortality, ICU admission and new course of antibiotic therapy rates did not differ between the two groups.
Fewer patients in the intervention group were readmitted for relapsing infection (3.4% vs. 7.9%, p 0.01). There was a trend for a shorter
length of hospital stay in patients suffering from community-acquired infections in the intervention group (5 days [3–10] vs. 6 days [3–14],
p 0.06). This study provides clinical evidence that a post-prescription antibiotic review followed by unsolicited IDP advice is effective in
reducing antibiotic exposure of patients and increasing the quality of antibiotic use, and may reduce hospital stay and relapsing infection
rates, with no adverse effects on other patient outcomes.
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Antibiotics are frequently prescribed in hospitals [1,2]. Up to
50% of antibiotic use is inappropriate, leading to considerable
costs related to patient care and potential selection of
resistant pathogens [2,3]. Therefore, antimicrobial stewardship
programmes (ASPs) must be implemented to optimize antibi-
otic use [4]. Among the recommended strategies, prospec-
tively auditing prescriptions by dedicated infectious disease
physicians (IDPs), followed by an intervention when judged
necessary with feedback to prescribers, has been shown to
reduce inappropriate use [5–14]. However, the clinical impact
of such intervention on patient outcomes has been rarely
evaluated [8]. Therefore treating physicians may be reluctant
to follow these unsolicited recommendations because the
safety of this approach has not been fully assessed [15].
At our hospital, we took advantage of the implementation
of a computerized prescription system in February 2006 to set
up a computer-generated listing of antibiotics prescribed in
surgical and medical wards. This allowed the IDP to perform
an unsolicited post-prescription review of selected antibiotic
orders in addition to the other components of our ASP
(detailed in online supplementary material, OLS) [16,17].
After implementation of the post-prescription review we
decided to perform a randomized controlled trial to evaluate
its clinical impact.
Patients and Methods
This was a randomized, controlled, open trial conducted over
a 6-month period in an 850-bed general university hospital.
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Overall hospital antibiotic consumption before starting the
study was 650 DDDs/1000 hospital days, which is in the low
range of antibiotic consumption among French university
hospitals of the Paris area. The study was approved by the
Institutional Review Board of our hospital, and patients
received oral and written information regarding the study
objectives and conduct. Physicians in charge of the patients
were informed by mail.
Inclusion and exclusion criteria
All patients hospitalized in surgical and medical wards (650
beds) were screened daily for possible inclusion in the study
using the computer-generated alert system previously
described [16]. The system allows daily review (on weekdays)
of all new prescriptions of any of 15 selected antibiotics of
intermediate or broad spectrum (listing is given in the OLS).
Medical and surgical wards represented 71% of total hospital
antibiotic prescription. Antibiotics selected accounted for 47%
of total antibiotic prescriptions of surgical and medical wards.
To be eligible, patients had to be treated with one of the
targeted antibiotics for at least 3 days (or up to 5 days if
prescriptions were initiated during bank holiday periods).
Patients were non-eligible if IDP advice had been requested by
staff physicians within the ﬁrst 3 days of initiating therapy for
the infectious episode considered, if they were suffering from
acute leukaemia or they had an expected survival of < 30 days.
Exclusion criteria between randomization and the start of the
intervention were discontinuation of any antibiotic therapy,
hospital discharge, and transfer to the ICU or death.
Randomization
Eligible patients were allocated to either the intervention or
the control group by using a computer-generated randomiza-
tion list, which was maintained independently of the IDP.
Concealment of the allocation was maintained, as the physician
in charge of the patient and the IDP were involved only after
randomization.
Intervention
A single IDP performed all interventions for eligible patients,
after screening the patient’s computerized chart. The inter-
vention consisted of a post-prescription review followed by
direct interaction with the prescribing physician. Predeﬁned
criteria for intervention are given in the online supplementary
material.
After reviewing the data the IDP provided the attending
physician with an oral recommendation to modify the antibi-
otic regimen when deemed appropriate. When advice could
not be given directly to the physician, recommendations were
written in the medical chart. These could be overridden and
no further attempt was made if recommendations were not
followed.
No intervention was made in the control group. In this
group, antibiotic management and re-evaluation was left to the
ward physician. However, the physician could request advice
from the IDP as needed.
Data collection
The following characteristics were collected from the patients’
charts by the same investigator (CL) independently of the IDP:
age, sex, dates of admission to and discharge from the hospital
or death (censored at 60 days after randomization), ICU
admission within the ﬁrst 7 days of randomization, the
Charlson co-morbidity score [18], results of microbiological
investigations, indication for antibiotic therapy and information
on the antibiotic prescription.
The actual duration of treatment was assessed, including the
duration of broad-spectrum or intermediate-spectrum antibiot-
ics, and of intravenous or oral administration. Any new course
of antibiotic therapy initiated 7 days or more after completion
of the initial course of treatment was recorded. Relapse of the
infection was assessed if readmission occurred within 60 days of
randomization, and considered when a new course of antibiotic
therapy administered for a documented or presumed infection
at the same site of infection was prescribed.
Outcomes
Two series of outcomes were assessed in the study. First, we
evaluated the potential clinical impact of both strategies, with
regard to length of hospital stay (the primary outcome), in-
hospital mortality, ICU admission, new course of antibiotic
therapy, and relapse of the infection [8]. Second, we evaluated
the quality of antibiotic use, which was estimated using the
following criteria: rate of early antibiotic re-evaluation (deﬁned
by any change of antibiotic therapy within 24 h of randomi-
zation), duration of treatment, use of antibiotic combination,
use of broad-spectrum antibiotics and oral switch [19].
Sample size
We hypothesized that the intervention might result in a 20%
reduction of the duration of hospitalization. The sample size was
estimated on the results of previous observations performed in
our hospital showing that the mean length of hospital stay for
patients treated with one of the targeted antibiotics was
15 ± 7 days. To detect a 20% reduction in the length of hospital
stay in the intervention groupwith a type I error of 5% and a type
II error of 80%, it was necessary to enrol a total of 506 patients
(253 patients in each group). We also found in our previous
study that 670 patients could be enrolled over 19 weeks. To
account for an estimated 15% exclusion of patients receiving IDP
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E91–E97
E92 Clinical Microbiology and Infection, Volume 19 Number 2, February 2013 CMI
advice upon the request of attending physicians during the ﬁrst
few days of therapy, and a further 15% loss due to secondary
exclusions of randomized patients, we planned on recruiting a
total of 900 subjects in a 24-week period.
Statistical analysis
Categorical variables were expressed as numbers and per-
centages and were compared using the Pearson v2 test or the
Fisher exact test, as appropriate. Continuous variables were
expressed as the median with interquartile range (IQR) and
were compared using the Mann–Whitney U-test. All statistical
tests were two-tailed and statistical signiﬁcance was set at
0.05. Analyses were performed by using the SPSS software,
version 11.5 (SPSS Inc., Chicago, IL, USA).
Results
During the study period, 1149 patients received one of the
targeted antibiotics for at least 3 days (Fig. 1); 294 patients were
excluded. A total of 855 patientswere randomly assigned to either
the intervention or the control group. The analysis was restricted
to 753 patients after secondary exclusion of 102 patients.
Patients’ characteristics
At baseline, the two groups were very similar regarding
demographic and clinical characteristics (Table 1). Most
patients had signiﬁcant but moderate co-morbidities. A large
majority suffered from mild to moderately severe infection.
Only 46% of the prescriptions were microbiologically docu-
mented and bacteraemia was recorded in 10% or less of
patients. The majority of infections were community acquired.
Most prescriptions were initiated for respiratory, urinary, skin
and soft tissue or digestive tract infections. There was no
difference in this distribution between the two groups.
Half of the antibiotic regimens were initially prescribed
intravenously by ward physicians. The majority of prescriptions
were of amoxicillin clavulanate, ﬂuoroquinolones and third-
generation cephalosporins.
IDP advice and early antibiotic re-evaluation
In the intervention group, 63.3% of prescriptions prompted
IDP interventions, including stopping therapy in the absence of
bacterial infection, shortening the planned duration, or
de-escalating broad-spectrum antibiotics (Table 2). Clinical
examination of the patients was performed for 42% of the
interventions. Time required, cost of the intervention and
Assessed for eligibility (n = 854)
Allocated to intervention
group (n = 424)
Allocated to control group
(n = 430)
Received allocated intervention (n = 376)
Did not receive allocated intervention (n = 48)
(Antibiotic discontinued n = 9; discharged
from hospital n = 30; ICU admission n = 6; died
before starting the intervention n = 3)
Analyzed (n = 376) Analyzed (n = 377)
Received allocated intervention (n = 377)
Did not receive allocated intervention (n = 53)
(Antibiotic discontinued n = 11; discharged
from hospital n = 37; ICU admission n = 2; died
before starting the intervention n = 3)
Lost to follow up (n = 0)
Discontinued intervention (n = 0)
Lost to follow up (n = 0)
Discontinued intervention (n = 0)
Screened (n = 1149)
Excluded (n = 294) (previous IDP advice, acute
leukaemia, expected survival <30 days)
FIG. 1. Study ﬂow diagram.
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antibiotic expenditures are given in the OLS. Most (90.3%) IDP
recommendations were adopted by ward physicians. In
contrast, IDP advice was rarely solicited by physicians (8% of
prescriptions) in the control group. Accordingly, most pre-
scriptions were left unchanged. Signiﬁcant differences were
observed between the two groups with regard to the rates of
stopping therapy, reducing the planned duration or
de-escalating therapy. However, switching to the oral route
was not more frequent in the intervention group.
Duration of antibiotic therapy
Consistent with the higher rates of stopping therapy or
reducing its planned duration, the IDP intervention led to a
signiﬁcant reduction of the median duration of antibiotic
therapy (Table 3). Of interest, a reduction was also observed
for the duration of intravenous administration and of broad-
spectrum antibiotics.
Clinical endpoints
The duration of hospitalization did not differ between the two
groups (median, 15 days). However, there was a trend for a
shorter duration of hospital stay for patients admitted with
community-acquired infections in the intervention group
(Table 4). No apparent detrimental effect was found associ-
TABLE 2. Rates of infectious disease physician (IDP) advice
and actual early (days 3–5) antibiotic modiﬁcation prescribed
by ward physicians in the two study groups
No. (%)
Control group
N = 377
Intervention group
N = 376 p value
Solicited IDP advice1 30 (8.0) 11 (2.9) 0.002
Unsolicited IDP review 0 (0.0) 315 (83.6) <0.0001
Antibiotic modiﬁcation
Any change 97 (25.7) 215 (57.1)2 <0.0001
Stopping therapy 15 (0.4) 59 (15.6) <0.0001
Shortening duration 24 (6.3) 65 (17.2) <0.0001
De-escalating3 9 (0.2) 72 (19.1) <0.0001
Oral switch4 47 (21.6) 48 (24.1) 0.90
Other5 24 (6.3) 30 (7.9) 0.39
1Patients were non-eligible if IDP advice had been requested by staff physicians
within the ﬁrst 3 days of initiating therapy for the infectious episode considered.
2Rate of compliance with IDP advice was 85.0%.
3Including reducing antibiotic spectrum and antibiotic combination.
4There were 218 and 199 initial intravenous prescriptions in each group
(Table 1a).
5Including increasing duration, changing the dosing regimen or switching to a
broader spectrum antibiotic.
TABLE 3. Duration of antibiotic therapy in the two study
groups, overall and for the antibiotic regimen subgroups
Median duration,
days (IQR)
Control
group N = 377
Intervention
group N = 376 p value
Total antibiotic course 7 (5–9) 6 (4–9) <0.0001
Broad-spectrum antibiotica 4 (0–7) 2 (0–5) 0.0003
Narrow to intermediate-
spectrum antibiotica
4 (0–8) 5 (0–7) 0.13
Intravenous administration 4 (0–8) 3 (0–6) 0.004
Oral therapy 4 (0–7) 4 (0–7) 0.84
aAntibiotic spectrum was classiﬁed as narrow to intermediate (amoxicillin/
clavulanate or aminoglycosides or glycopeptides-linezolid) or broad spectrum
(third-generation cephalosporins, piperacillin/tazobactam, imipenem or ﬂuoroqu-
inolones).
TABLE 4. Clinical outcomes of patients in the two study
groups
Control
group
N = 377
Intervention
group N = 376 p value
60 days in-hospital
mortality, n (%)
38 (10.1) 37 (9.8) 0.91
ICU admission within
7 days of randomization, n (%)
6 (1.6) 7 (1.9) 0.78
New course of antibiotic
therapy, n (%)
25 (6.6) 17 (4.5) 0.21
Antibiotic treatment for
relapsing infection, n (%)
30 (7.9) 13 (3.4) 0.01
Length of stay, days (median, IQR)
Overall population 15 (9–27) 15 (9–25) 0.95
Community-acquired infection 6 (3–14)a 5 (3–10)b 0.06
a260 patients.
b249 patients.
TABLE 1. (a) Patients’ demographics and clinical character-
istics of infection in patients randomized to the intervention
and control groups. (b) Microbiological documentation of
infection and antibiotics prescribed
Control group
N = 377
Intervention
group
N = 376 p value
(a)
Ward
Surgical 126 (33.4) 129 (34.3) 0.8
Medical 251 (66.6) 247 (65.7)
Sex
Male 237 (62.9) 226 (60.1) 0.48
Female 140 (37.1) 150 (39.9)
Age, median (IQR) 66 (53–78) 67 (54–78) 0.68
Charlson score, median (IQR) 2 (1–3) 2 (1–4) 0.23
Severe sepsis or septic shock 6 (1.6) 8 (2.2) 0.18
Hospital-acquired infection 117 (31.0) 127 (33.8) 0.42
Bacteraemia 27 (7.2) 40 (10.6) 0.094
Clinical source of infection
None identiﬁed 48 (12.7) 52 (13.8) 0.87
Lower respiratory tract 78 (20.7) 80 (21.3)
Digestive tract 52 (13.8) 45 (12.0)
Urinary tract 94 (24.1) 89 (23.7)
Skin and soft tissues 58 (15.4) 60 (15.9)
Intravascular1 12 (3.2) 19 (5.0)
Bone and joint 5 (1.3) 5 (1.3)
Other sites 33 (8.7) 26 (6.9)
(b)
Antibiotic initially prescribed
Amoxicillin clavulanate 178 (47.2) 204 (54.2) 0.60
Third-generation cephalosporins 83 (22.0) 66 (17.6)
Fluoroquinolones 75 (19.9) 66 (17.6)
Aminoglycosides 2 (0.5) 4 (1.1)
Piperacillin tazobactam 18 (4.8) 18 (4.8)
Imipenem 11 (2.9) 9 (2.4)
Vancomycin, linezolid 10 (2.6) 9 (2.4)
Intravenous administration 218 (57.8) 199 (52.9) 0.17
Microbiological documentation
Present 169 (44.8) 183 (48.7) 0.44
Gram-positive cocci 40 (10.6) 37 (9.8)
Enterobacteriacae 82 (21.8) 84 (22.3)
Pseudomonas aeruginosa 9 (2.4) 7 (1.9)
Others 9 (2.4) 9 (2.4)
Polymicrobial infection 29 (7.7) 46 (12.2)
Multidrug-resistant bacteria2 19 (5.0) 11 (3.0) 0.14
Data are shown as No. (%), unless otherwise speciﬁed.
1Includes primary bacteraemia, catheter-related infection and endocarditis.
2Methicillin-resistant Staphylococcus aureus, extended-spectrum b-lactamase pro-
ducing Enterobacteriacae, multidrug-resistant P. aeruginosa and Acinetobacter
baumanii.
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ated with the lower antibiotic exposure of patients: in-hospital
mortality and ICU admission rates did not differ between the
two groups. Similarly, new courses of antibiotic therapy
prescribed 7 days or more after completion of the ﬁrst
treatment course were not more frequent in the intervention
group. Of note, more patients in the control group were
readmitted with relapsing infection within the 2 months
following randomization. Rate of secondary infection and/or
colonization due to multidrug-resistant bacteria did not differ
between the two groups (see the OLS). Clinical outcomes of
patients according to the adoption of the IDP advice in the
intervention group are shown in the OLS.
Discussion
In this randomized controlled study evaluating the impact of an
ASP on the outcomes of patients, we found that the
intervention resulted in reduced overall antibiotic exposure
of patients without apparent adverse effects, and a suggestion
of a better outcome with a lower rate of readmissions with
relapsing infection. There was, however, no effect of the
intervention on the primary outcome selected (length of
hospital stay) or on mortality rate, although the former tended
to be shorter in patients with community-acquired infection.
Prospective audit with interaction with and feedback to the
prescribers has been shown to optimize antimicrobial use
[12,20–22]. However, a limited number of studies have
examined clinically relevant patient outcomes associated with
the implementation of an ASP, and most of these were
underpowered or uncontrolled before–after studies [8,23].
While most data from these studies have been reassuring,
some have pointed out an increased risk of readmission
[20,21,24–27].
In this study, we evaluated the clinical outcomes and safety of
a systematic but unsolicited review of antibiotic prescriptions
performed by an IDP in surgical and medical wards. The aims of
the intervention were to optimize therapy while reducing
overall antibiotic exposure, mainly by reducing the number and
duration of antibiotic prescriptions or de-escalating broad-
spectrum or antibiotic combination regimens, and to assess the
safety of this approach. A number of clinically relevant outcomes
were assessed in this study, including length of hospital stay, 60-
day in-hospital mortality, ICU admission rate and readmission
rates with or without infection, some of which (i.e. in-hospital
mortality and rates of readmission for relapsing infection) were
selected on the basis of previous studies [8]. As pointed out by
McGowan, studies focusing solely on decreased antimicrobial
use have failed to show improvement in clinical outcome [28].
We hypothesized that physicians were less likely to comply with
the ‘reducing duration’ advice because of concerns regarding
early worsening of their patients with shortening the duration of
therapy. Therefore, we decided to incorporate two potential
markers of early clinical failure, ICU referral rate after random-
ization and new courses of antibiotic therapy after completion of
treatment. Finally, length of hospital staywas compared between
the two groups because some studies have suggested that
review and feedback strategies may reduce the duration of
hospitalization [7].
Consistent with previous studies, we found that IDP inter-
vention was associated with a higher rate of early antibiotic
modiﬁcation, resulting in less antibiotic exposure for patients
and lower use of broad-spectrum or antibiotic combination
regimens. Of note, the higher antibiotic withdrawal rate in the
intervention group was not associated with adverse effects for
patients: the rates of ICU admissions after randomization and
new courses of antibiotic therapywere similar in the control and
intervention groups. The same positive effect was previously
reported by authors investigating an antibiotic discontinuation
policy for ventilator-associated pneumonia [29]. Inadequate
antimicrobial treatment of infections has been shown to be an
important determinant of hospital mortality [30]. With regard
to this ﬁnding, it was reassuring to ﬁnd that the in-hospital death
rate was not higher in the intervention group, consistent with
previous ﬁndings [20,21,24,31]. Furthermore, we assessed the
relapse rate of infection. Indeed, in one study, a programme
aimed at discontinuing intravenous antibiotics was associated
with a signiﬁcantly higher readmission rate, albeit not considered
as infection related by the authors; other studies did not report
an increased risk of hospital readmission [20,21,26,27]. In
contrast, we found that patients randomized to the IDP
intervention group were less frequently readmitted with
relapsing infection.
Wewere unable to show a reduction in length of hospital stay
associated with the intervention. Whether interventions aimed
at reducing patients’ antibiotic exposure may also reduce the
length of hospital stay is controversial. Previous studies evalu-
ating interventions directed at reducing intravenous antibiotic
use have shown variable results, including a signiﬁcant effect, a
trend toward a shorter length of stay or no effect at all
[21,24,31]. In this study, we did not observe a reduction in the
length of hospital stay in the intervention group, similar to the
ﬁndings by Salomon et al. [20]. There can be several explanations
for these ﬁndings: ﬁrst, intravenous antibiotics accounted for
only 55% of the prescriptions at the time of the intervention;
second, the rate of early oral switch was not higher in the
intervention group; and third, our patient population included a
mix of patients with both community-acquired (68%) and
hospital-acquired (32%) infections, in whom infection may not
be the sole reason for hospitalization. Finally, length of stay is not
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an ideal endpoint, as it can be inﬂuenced by several factors other
than management of infection, such as co-morbidities and
availability of outpatient care. Nevertheless, there was a trend
toward a shorter length of stay for patients hospitalized with
community-acquired infections in the intervention group
(p 0.06), but our study lacked the power to detect a signiﬁcant
difference regarding this outcome.
Strengths of our study include its randomized and con-
trolled design and the assessment of a number of clinical
outcomes, but some limitations should be considered. First, it
was performed in a single institution by the same IDP and the
results may not be applicable to other hospitals. Because we
did not randomize treating physicians, contamination occurring
between the intervention and control groups may have
diminished the effects of the intervention. Finally, we did not
ﬁnd an ecological beneﬁt of the intervention as suggested by
others [3,12,24,31]. As patients were not followed-up after
hospital discharge, we may not have captured all potential
relapses of infection, and these were only assessed at time of
readmission in patients readmitted within 60 days of discharge.
In summary, our study provides evidence in the clinical
setting that a post-prescription antibiotic review followed by
unsolicited IDP advice can be successfully implemented in
hospitals, is not associated with adverse effects, and may
actually have beneﬁcial effects on outcomes of patients. Our
results support the contention that this strategy should be
integrated into ASPs wherever possible.
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